Prot #27918: A phase III, Double-Blind, Placebo-Controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/day) and High (100 mg/day) Dose of Safinamide, as Add-on Therapy, in Subjects with Early Idiopathic Parkinson's Disease Treate